Makati begins online registration for Sinovac vaccine

enablePagination: false
maxItemsPerPage: 10
maxPaginationLinks: 10

Metro Manila (CNN Philippines, February 27) — Makati City on Saturday opened its pre-registration system for constituents who wish to avail of the COVID-19 vaccine made by Chinese firm Sinovac.

Those interested could visit this website to reserve a slot, the local government said in a Facebook post.

The website provides instructions for prospective vaccine recipients. It said patients who had history of COVID-19 may register three months after they were diagnosed with the infectious disease. Those exhibiting symptoms, meanwhile, are advised to seek consultation in a health center and go through self-quarantine before signing up, and people who previously received another type of vaccine should wait for a month before registering.

The local government said the Sinovac vaccine doses are from the national government, adding it will follow the prioritization protocol set by the Department of Health and the Inter-Agency Task Force, the policy-making body in the COVID-19 response. Medical frontliners in private and public health facilities are first in line for the vaccines, followed by other frontliners in the health sector such as nursing aides, janitors, and barangay health workers. Next are people with comorbidities, then front-line personnel in essential sectors such as police personnel and soldiers. Others are the indigent group and remaining population.

China promised to give a total of 600,000 doses of Sinovac's CoronaVac to the country. A fraction or 100,000 of the donated doses will go to the Department of National Defense. Officials said the vaccine shipment will arrive on Sunday, Feb. 28.

The Sinovac vaccine is authorized for emergency use in the country. The Food and Drug Administration recommended giving CoronaVac to clinically healthy individuals aged 18-59.

FDA Director General Eric Domingo said early this week CoronaVac is not recommended for medical workers exposed to COVID-19 patients because it showed a low efficacy rate of 50.4% in late-stage trials in Brazil. But Health spokesperson Maria Rosario Vergeire later said that while clinical trials show lower efficacy in preventing mild symptoms, CoronaVac is still 100% effective against moderate and severe symptoms.

The anti-coronavirus shots of Pfizer-BioNTech and AstraZeneca, which have shown higher efficacy than CoronaVac at 95% and 82% respectively, were the first two to receive emergency use authorization from the Food and Drug Administration. Officials have yet to give exact dates as to the dates of arrival of these shots.